SEARCH:   Advanced

Blood, 1 March 2007, Vol. 109, No. 5, pp. 1862-1869. Prepublished online as a Blood First Edition Paper on November 14, 2006; DOI 10.1182/blood-2006-03-013151. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2006-03-013151v1 109/5/1862    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bray, P. F. Articles by Herrington, D. M. Search for Related Content PubMed PubMed Citation Articles by Bray, P. F. Articles by Herrington, D. M. Related Collections Cell Adhesion and Motility Signal Transduction Clinical Trials and Observations Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Effect of genetic variations in platelet glycoproteins Ib and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy Paul F. Bray1, Timothy D. Howard2, Eric Vittinghoff3, David C. Sane2, and David M. Herrington2 1 Jefferson Medical College and the Cardeza Foundation for Hematologic Research, Philadelphia, PA; 2 Wake Forest University School of Medicine, Winston-Salem, NC; 3 University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA Millions of women still use postmenopausal hormone therapy (HT). We genotyped 2090 women in Heart and Estrogen/progestin Replacement Study for functional polymorphisms in GP1BA and GP6 and assessed the coronary heart disease (CHD) event rate over 5.8 years of follow-up. In patients receiving placebo, there was an increased CHD death/myocardial infarction (MI)/unstable angina (UA) event rate in carriers of the GP1BA –5C allele (adjusted [adj] P = .006). HT increased the hazard ratio (HR) of CHD events in patients with the GP1BA –5TT genotype by 16% and reduced the HR in patients with the TC+CC genotypes by 46% (adj interaction P < .001). HT reduced the HR in patients with the GP6 13254TT genotype by 17% but increased the HR in patients with the TC+CC genotypes by 35% (adj interaction P < .001). Furthermore, HT increased the HR of CHD events in patients with the GP1BA –5TT plus GP6 13254TC+CC genotypes by 57% and reduced the HR in patients with the GP1BA –5TC+CC plus GP6 13254TT genotypes by 55% (adj interaction P < .001). In postmenopausal women with established CHD, these polymorphisms of platelet genes were predictors of CHD events and significantly modified the effects of HT on CHD risk. It will be important to replicate these findings in other studies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. E. Freedman Heritability, Platelet Function, and Aspirin: A Link Established but Cause Unknown Circulation, May 15, 2007; 115(19): 2468 - 2470. [Full Text] [PDF] Platelet Polymorphisms Alter Risk for Adverse Coronary Events in Women Receiving HT Journal Watch Oncology and Hematology, March 19, 2007; 2007(319): 3 - 3. [Full Text]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020